CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

lake erie medical surgical & supply dba quality care products llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short-term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

rebel distributors corp. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

eli lilly and company - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - cymbalta® is indicated for the treatment of: - major depressive disorder in adults - generalized anxiety disorder in adults and pediatric patients 7 years of age and older - diabetic peripheral neuropathic pain in adults - fibromyalgia in adults and pediatric patients 13 years of age and older - chronic musculoskeletal pain in adults the use of maois intended to treat psychiatric disorders with cymbalta or within 5 days of stopping treatment with cymbalta is contraindicated because of an increased risk of serotonin syndrome. the use of cymbalta within 14 days of stopping an maoi intended to treat psychiatric disorders is contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] . starting cymbalta in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . pregnancy exposure registry there

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

physicians total care, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine hydrochloride 20 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation.   cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] .   generalized anxiety disorder is

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

pd-rx pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 60 mg - cymbalta ® is indicated for the treatment of: - major depressive disorder [see clinical studies ( 14.1)] - generalized anxiety disorder [see clinical studies ( 14.2)] - diabetic peripheral neuropathy [see clinical studies ( 14.3)] - fibromyalgia [see clinical studies ( 14.4)] - chronic musculoskeletal pain [see clinical studies ( 14.5)] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with cymbalta or within 5 days of stopping treatment with cymbalta is contraindicated because of an increased risk of serotonin syndrome. the use of cymbalta within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration ( 2.8) and warnings and precautions ( 5.4)] . starting cymbalt

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

stat rx usa llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short-term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

rebel distributors corp - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short-term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

lake erie medical dba quality care products llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 60 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short-term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

h.j. harkins company, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 60 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short-term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

CYMBALTA- duloxetine hydrochloride capsule, delayed release United States - English - NLM (National Library of Medicine)

cymbalta- duloxetine hydrochloride capsule, delayed release

pd-rx pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - cymbalta ® is indicated for the treatment of: - major depressive disorder [see clinical studies ( 14.1)] - generalized anxiety disorder [see clinical studies ( 14.2)] - diabetic peripheral neuropathy [see clinical studies ( 14.3)] - fibromyalgia [see clinical studies ( 14.4)] - chronic musculoskeletal pain [see clinical studies ( 14.5)] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with cymbalta or within 5 days of stopping treatment with cymbalta is contraindicated because of an increased risk of serotonin syndrome. the use of cymbalta within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration ( 2.8) and warnings and precautions ( 5.4)] . starting cymbalt